Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Shares Outstanding (Weighted Average): 2015-2025

Historic Shares Outstanding (Weighted Average) for Editas Medicine (EDIT) over the last 10 years, with Sep 2025 value amounting to $89.9 million.

  • Editas Medicine's Shares Outstanding (Weighted Average) rose 9.03% to $89.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.9 million, marking a year-over-year increase of 9.03%. This contributed to the annual value of $82.5 million for FY2024, which is 1.07% up from last year.
  • Latest data reveals that Editas Medicine reported Shares Outstanding (Weighted Average) of $89.9 million as of Q3 2025, which was up 7.41% from $83.7 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Shares Outstanding (Weighted Average) registered a high of $89.9 million during Q3 2025, and its lowest value of $67.4 million during Q1 2021.
  • In the last 3 years, Editas Medicine's Shares Outstanding (Weighted Average) had a median value of $82.2 million in 2024 and averaged $80.6 million.
  • Data for Editas Medicine's Shares Outstanding (Weighted Average) shows a peak YoY grew of 23.33% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Editas Medicine's Shares Outstanding (Weighted Average) stood at $68.4 million in 2021, then grew by 0.53% to $68.8 million in 2022, then climbed by 18.78% to $81.7 million in 2023, then climbed by 1.07% to $82.5 million in 2024, then rose by 9.03% to $89.9 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $89.9 million for Q3 2025, versus $83.7 million for Q2 2025 and $83.0 million for Q1 2025.